Man

Cristian Andres Soza Ried

Director Ciéntidfico (CSO)

Positronpharma SA

Santiago, Chile

Líneas de Investigación


Educación

  •  Immunology , Max-Planck-Institut für Immunbiologie und Epigenetik . Chile, 2008
  •  Genetics, UNIVERSIDAD DE CHILE. Chile, 2003
  •  Data Science, Universidad de las Américas. Chile, 2022
  •  Advance biostatistics, PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE. Chile, 2019
  •  Biostatistics, PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE. Chile, 2018
  •  Psycho-oncology , UNIVERSIDAD AUSTRAL DE CHILE. Chile, 2014
  •  Ingeniero en Acuicultura, UNIVERSIDAD ANDRES BELLO. Chile, 2000

Experiencia Académica

  •   Profesor adjunto Other

    Universidad Andres Bello

    Medicina

    Santiago, Chile

    2000 - 2021

  •   Profesor asistente Other

    Universidad San Sebastián

    Ciencias

    Santiago, Chile

    2015 - A la fecha

  •   Profesor adjunto Other

    Universidad de las Americas

    Medicina Veterinaria y Agronomía

    Santiago, Chile

    2019 - A la fecha

  •   Profesor adjunto Other

    Universidad Bernardo O`Higgins

    Ciencias

    Santiago, Chile

    2018 - 2023

Experiencia Profesional

  •   Director Científico (CSO) Part Time

    Positronpharma SA

    Santiago, Chile

    2021 - A la fecha

  •   Investigador asociado Part Time

    PositronMed

    Santiago, Chile

    2018 - A la fecha

  •   Vice-president of Discovery Other

    Therakles Pharmaceuticals AG

    Suiza

    2024 - A la fecha

  •   Miembro del directorio Other

    Fundación Oncoloop

    Santiago, Chile

    2015 - Sin Información

  •   Investigador asociado Part Time

    Fundación Arturo López Pérez

    Santiago, Chile

    2015 - 2018

  •   Postdoctorado Full Time

    Cancer Research UK. London Research Institute

    Londres, Reino Unido

    2009 - 2014

  •   Investigador postgrado Full Time

    Universidad de Chile, Fundación Ciencias para la Vida

    Santiago, Chile

    1999 - 2003

  •   Postdoctorado Full Time

    Max-Planck Institute of Immunobiology and Epigenetics

    Alemania

    2008 - 2009

Formación de Capital Humano


0


Premios y Distinciones

  •   Max-Planck Fellowship

    MAX PLANCK SOCIETY

    Alemania, 2003

    PhD Fellowship

  •   Postodctoral Fellowship

    MAX PLANCK SOCIETY

    Chile, 2008

    Postdoctoral Fellowship

  •   Postdoctoral Fellowship

    Cancer Research UK

    Reino Unido, 2009

    Postodoctoral Fellowship


 

Article (27)

Biodistribution and dosimetry of [177Lu]Lu-SibuDAB in patients with metastatic castration-resistant prostate cancer
Image-based machine learning model as a tool for classification of [18F]PR04.MZ PET images in patients with parkinsonian syndrome
Safety and efficacy of [177Lu]Lu-SibuDAB in patients with progressive metastatic castration-resistant prostate cancer
Antagonistic interactions safeguard mitotic propagation of genetic and epigenetic information in zebrafish
Imaging GRPr Expression in Metastatic Castration-Resistant Prostate Cancer with [68Ga]Ga-RM2-A Head-to-Head Pilot Comparison with [68Ga]Ga-PSMA-11
Initial results with [18F]FAPI-74 PET/CT in idiopathic pulmonary fibrosis
Oncological Patients' Perception of Received Information: Adaptation and Psychometric Evaluation of the EORTC QLQINFO25 Questionnaire in Chilean Patients
Al[18F]F-NOTA-Octreotide Is Comparable to [68Ga]Ga-DOTA-TATE for PET/CT Imaging of Neuroendocrine Tumours in the Latin-American Population
Head-to-Head Intra-Individual Comparison of Biodistribution and Tumor Uptake of [18F]FAPI-74 with [18F]FDG in Patients with PDAC: A Prospective Exploratory Study
[F-18]PR04.MZ PET/CT Imaging for Evaluation of Nigrostriatal Neuron Integrity in Patients With Parkinson Disease
Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC
Diagnostic accuracy of 18F-PSMA-1007 PET/CT imaging for lymph node staging of prostate carcinoma in primary and biochemical recurrence
Evaluation of safety and dosimetry of 177Lu-DOTA-ZOL for therapy of bone metastases
Genetic landscape of T cells identifies synthetic lethality for T-ALL
Characterization of the serotonin 2A receptor selective PET tracer (R)-[F-18]MH.MZ in the human brain
Pharmacokinetic evaluation of [18F]PR04.MZ for PET/CT imaging and quantification of dopamine transporters in the human brain
Triple-negative breast cancer: the reality in Chile and in Latin America
Evidence of response to pembrolizumab in a patient with lynch syndrome-related metastatic colon cancer
Forward Genetic Screens in Zebrafish Identify Pre-mRNA-Processing Pathways Regulating Early T Cell Development
Stochastic Regulation of her1/7 Gene Expression Is the Source of Noise in the Zebrafish Somite Clock Counteracted by Notch Signalling
Pulses of Notch activation synchronise oscillating somite cells and entrain the zebrafish segmentation clock
DeltaC and DeltaD interact as Notch ligands in the zebrafish segmentation clock
Genetic Evidence for an Evolutionarily Conserved Role of IL-7 Signaling in T Cell Development of Zebrafish
Essential role of <i>c</i>-<i>myb</i> in definitive hematopoiesis is evolutionarily conserved
Maintenance of thymic epithelial phenotype requires extrinsic signals in mouse and zebrafish
Production and immune response of recombinant Hsp60 and Hsp70 from the salmon pathogen Piscirickettsia salmonis
Chilean experience using “Theranostics” for treating metastatic neuroendocrine tumors with [177Lu]Lu DOTA-TATE.

Abstract (6)

Ad-hoc analysis of [18F]FAPI-74 imaging in patients with sarcoma within an ongoing prospective basket-trial
Clinical translation of the albumin-binding radioligand 177Lu-(S)-Ibu-DAB-PSMA in patients with mCRPC: Enhancing clinical efficacy of PSMA-targeted RLT
Comparison of the quadratic scheme suggested by EANM guidelines and manufacturer-recommended dose factor for Fluorine-18 FDG imaging on PET-CT system with SiPM detectors: evaluation on image quality
Normalizing SUV values by lean body mass effectively reflect patient weigt and body composition variations improving SUVmax values determination in 18F-FDG PET-CT imaging.
Comparison of Al[18F]F-NOTA-octreotide and [68Ga]Ga-DOTATATE in Neuroendocrine Tumors
F-18-PSMA-1007 PET/CT in stating of primary prostate cancer: correlation between SUVmax and both PSA level and Gleason score

Correction (1)

Antagonistic interactions safeguard mitotic propagation of genetic and epigenetic information in zebrafish (vol 7, 31, 2024)

Note (1)

Management plan for breast cancer during the COVID-19 pandemic. A single-institution alternative to treat early breast cancer patients in a short time

Review (2)

Unraveling the complex link between vitamin D levels and cancer: A crucial understanding for designing future supplementation approaches
Oncogenic role of arsenic exposure in lung cancer: A forgotten risk factor
2
Luis Burzio

Scientific Director

Andes Biotechnologies

FUNDACION CIENCIA PARA LA VIDA

Santiago, Chile

1
Pablo Valenzuela

Founder and Scientific Director

Fundación Ciencia & Vida

Santiago, Chile

3
CARLOS JURI

Profesor Asociado

Neurología

PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE

SANTIAGO, Chile

1
Mario Rosemblatt

Executive Director

-

Fundacion Ciencia & Vida

Santiago, Chile

2
Pedro Chana Cuevas

Profesor Titular

Facultad de Ciencias Medicas

Universidad de Santiago

Santiago, Chile

1
Roberto Estay

Oncólogo médico

Oncología

Hospital del Salvador

Santiago, Chile

4
Vasko Kramer

Head of R&D

Investigación y Desarrollo

Positronmed Ltd. (Prestaciones Medicas AyC Ltda.)

Santiago, Chile

1
Carlos Gallardo

JEFE TECNICO

INVESTIGACION DEL CANCER

CLINICA ONCOLOGIA FUNDACION ARTURO LOPEZ PEREZ

SANTIAGO, Chile

1
Hugo Marsiglia

Director Relaciones Médicas Internacionales

Fundación Arturo López Pérez

Santiago, Chile

2
Pamela Salman

Full Professor

Facultad de Medicina y Ciencias de la Salud

Universidad Mayor de Chile

Santiago, Chile

37
Cristian Soza

Director Ciéntidfico (CSO)

Research and Development

Positronpharma SA

Santiago, Chile